The purpose of this study is confirmatory investigation of safety and efficacy of FYU-981 administered orally to hyperuricemic patients with and without gout for 34 or 58 weeks by the method of multicenter, open label and ascending dose regimen.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
330
Unnamed facility
Tokyo, Japan
Percent reduction from baseline in serum urate level at the final visit
Time frame: 34 or 58 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.